And ACBI1 treatment only impacted cell growth of cancer cell lines known to depend on BRG1/BRM function—an effect that could be blocked by addition of a competing bromodomain ligand—demonstrating notable specificity and selectivity in the action of ACBI1 [16]. This evidence concerns the gene SMARCA2 and cancer.